SOSOROS FUND MANAGEMENT LLC
Founded by George Soros · Portfolio as of Q2 2024
Top Holdings177 positions
STATE STR SPDR S&P 500 ETF T | 450,000 | $244.9M | 4.4% | $530.32 | 0.00% | 1 qtr | New 85 |
| 198.4M | $194.9M | 3.5% | — | — | — | Increased 58 | |
ISHARES TR | 2.5M | $192.9M | 3.5% | — | — | — | Unchanged — |
ASTRAZENECA PLC | 2.5M | $191.2M | 3.4% | $148.92 | +2.06% | 2 qtrssince 2024-Q1 | Increased 90 |
WESTROCK CO | 3.3M | $168M | 3.0% | — | — | 2 qtrssince 2024-Q1 | Increased 90 |
ALPHABET INC | 914,942 | $166.7M | 3.0% | $105.64 | +71.00% | 21 qtrssince 2019-Q2 | Decreased 0 |
STATE STR SPDR S&P 500 ETF T | 300,000 | $163.3M | 2.9% | — | — | — | Increased — |
APPLE INC | 750,000 | $158M | 2.8% | — | — | — | New — |
AERCAP HOLDINGS NV | 1.6M | $145.1M | 2.6% | $62.93 | +46.21% | 6 qtrssince 2023-Q1 | Decreased 0 |
| 134.5M | $121.7M | 2.2% | — | — | — | Decreased 0 | |
AXONICS INC | 1.8M | $119.3M | 2.1% | — | — | 2 qtrssince 2024-Q1 | Increased 83 |
| 138.3M | $100.2M | 1.8% | — | — | — | Unchanged 0 | |
CEREVEL THERAPEUTICS HLDNG I | 2.2M | $88M | 1.6% | — | — | 2 qtrssince 2024-Q1 | Increased 52 |
COSTCO WHOLESALE CORPORATION | 100,000 | $85M | 1.5% | — | — | — | New — |
| 90.8M | $84.8M | 1.5% | — | — | — | Unchanged 0 | |
CHAMPIONX CORPORATION | 2.5M | $81.9M | 1.5% | — | — | 1 qtr | New 68 |
| 84.8M | $78.4M | 1.4% | — | — | — | Increased 53 | |
LIBERTY BROADBAND CORP | 1.4M | $76.2M | 1.4% | — | — | 23 qtrssince 2018-Q4 | Unchanged 0 |
ALIBABA GROUP HLDG LTD | 1M | $73.8M | 1.3% | $70.80 | 0.00% | 1 qtr | New 68 |
| 131.5M | $73.5M | 1.3% | — | — | — | Decreased 0 |
SOROS FUND MANAGEMENT LLC manages $5.6B across 177 positions as of Q2 2024. Top holdings: SPY (4.4%), RIVIAN AUTOMOTIVE INC (3.5%), HYG puts (3.5%). Fund DNA: Momentum Trader. HoldingsIntel Score: 1.5/5.0.
Active quarter - 49 new positions, 54 exits, 51 increased. Top move: AZN (INCREASED, conviction 90). Portfolio: $5.6B across 177 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR